[HTML][HTML] Trends and characteristics of global initiative for chronic obstructive lung disease guidelines-Discordant prescribing of triple therapy among patients with …
SP Bhatt, C Blauer-Peterson, EK Buysman… - … Diseases: Journal of …, 2022 - ncbi.nlm.nih.gov
Background: Triple therapy (long-acting muscarinic antagonist [LAMA] plus long-acting
beta2-agonist [LABA] plus inhaled corticosteroid [ICS]) is recommended by the Global …
beta2-agonist [LABA] plus inhaled corticosteroid [ICS]) is recommended by the Global …
Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on …
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report
for the management of chronic obstructive pulmonary disease (COPD) focuses on reducing …
for the management of chronic obstructive pulmonary disease (COPD) focuses on reducing …
Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy
SR Palli, M Frazer, M DuCharme, AR Buikema… - Journal of Managed …, 2020 - jmcp.org
BACKGROUND: The 2018 Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommends combination long-acting muscarinic antagonists/long-acting beta2-agonists …
recommends combination long-acting muscarinic antagonists/long-acting beta2-agonists …
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or …
BACKGROUND: Clinical practice guidelines recommend dual long-acting muscarinic
antagonists (LAMAs)/long-acting β2agonists (LABAs) as maintenance therapy in patients …
antagonists (LAMAs)/long-acting β2agonists (LABAs) as maintenance therapy in patients …
Costs and clinical consequences of compliance with COPD GOLD recommendations or national guidelines compared with current clinical practice in Belgium …
S Sethi, A Wright, ES Hartgers-Gubbels… - … Journal of Chronic …, 2022 - Taylor & Francis
Purpose The objective of this study was to assess the clinical and cost benefits of treating
patients with chronic obstructive pulmonary disease (COPD) according to global and …
patients with chronic obstructive pulmonary disease (COPD) according to global and …
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate …
Background ATS and GOLD guidelines recommend treating low-exacerbation risk COPD
patients with dual (LAMA/LABA) agents and reserving triple therapy (TT; LAMA/LABA and …
patients with dual (LAMA/LABA) agents and reserving triple therapy (TT; LAMA/LABA and …
[PDF][PDF] 肺炎支原体肺炎合并喘息患儿血清25 (OH) D3 水平与肺功能的相关性及其影响因素分析
李佳潞， 杨俊， 朱晓萍， 李波， 陆婉秋 - 现代生物医学进展, 2021 - biomed.cnjournals.com
摘要目的: 探讨肺炎支原体肺炎(MPP) 患儿合并喘息的影响因素, 分析血清25-羟维生素D3 [25
(OH) D-3] 水平与MPP 合并喘息患儿肺功能的关系. 方法: 选择2017 年1 月至2020 年1 …
(OH) D-3] 水平与MPP 合并喘息患儿肺功能的关系. 方法: 选择2017 年1 月至2020 年1 …
Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
JAE Walters, EH Walters - Cochrane Database of Systematic …, 2023 - cochranelibrary.com
Background Management of chronic obstructive pulmonary disease (COPD) commonly
involves a combination of long‐acting bronchodilators including beta2‐agonists (LABA) and …
involves a combination of long‐acting bronchodilators including beta2‐agonists (LABA) and …
[PDF][PDF] 噻托溴铵辅助治疗呼吸窘迫综合征对血清NO 与VEGF 水平的影响研究
高琳， 李倩， 王丽， 雷靖， 谭焰 - Progress in Modern …, 2021 - biomed.cnjournals.com
摘要目的: 探讨与研究噻托溴铵辅助治疗呼吸窘迫综合征对血清一氧化氮(Nitric oxide, NO)
与血管内皮生长因子(vascular endothelial growth factor, VEGF) 水平的影响. 方法: 2016 年9 …
与血管内皮生长因子(vascular endothelial growth factor, VEGF) 水平的影响. 方法: 2016 年9 …
Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
J Cook, C Bloom, J Lewis, Z Marjenberg… - Journal of Market …, 2021 - Taylor & Francis
Background: Evidence suggests that triple therapy for patients with chronic obstructive
pulmonary disease (COPD) is being used in a broader range of patients than recommended …
pulmonary disease (COPD) is being used in a broader range of patients than recommended …